Therefore, the present study provided a novel signature featuring six PRGs (CASP3, ELANE, GSDMA, PYCARD, VDR, and NOD1) that exactly and independently predict OS in AML patients, which will further contribute to driving the progress of individualized prevention and treatment of AML. This evidence concerns the gene NOD1 and acute myeloid leukemia.